Ionis Pharmaceuticals (NASDAQ:IONS) Target Lowered by Morgan Stanley to $31.00

Ionis Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $31.00. The analysts previously had $33.00 target price. Morgan Stanley’s price target would indicate a potential upside of -9.91% from the stock’s previous close.

Shares of traded on monday, reaching $34.26. 73365 shares of the stock traded hands, compared to its average volume of 895199. On monday, Shares of closed at $34.26. The firm’s 50 day moving average is 37.18 and its 200 day moving average is 44.02.  has a 12 month low of $32.15 and a 12 month high of $64.37. While on yearly highs and lows, today has traded high as $34.40 and has touched $33.84 on the downward trend.

Earnings and What to expect: 

Ionis Pharmaceuticals last posted its quarterly earnings results on August 4th, 2021. The reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01. The firm earned $126 million during the quarter, compared to analyst estimates of $128.46 million. Its revenue for the quarter was down 13.7% compared to the same quarter last year. Ionis Pharmaceuticals has generated ($3.23) earnings per share over the last year (($3.87) diluted earnings per share). Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($1.81) to ($1.38) per share. Ionis Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($1.81) to ($1.38) per share. The P/E ratio of Ionis Pharmaceuticals is -8.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Ionis Pharmaceuticals is -8.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Ionis Pharmaceuticals has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NASDAQ:IONS) Moving Average Technical Analysis

5 day Moving Average is $33.68 And 5 day price change is 2.08 (6.43%)  with average volume for 5 day average is 609,640. While technical analysis for average 20 days shows significant difference, 20 day moving average is  35.04 and 20 day price change is -1.86 (-5.13%) and average 20 day moving volume is 948,270. 50 day moving average is 37.18  and 50 day price change is -2.73 ( -7.35%)  and with average volume for 50 days is : 814,984. 200 day moving average is 44.02  and 200 day price change is -25.86 (-42.91%)  and with average volume for 200 days is : 1,262,465.

Other owners latest trading in Ionis Pharmaceuticals :

  • On 10/7/2021 shares held by Berman Capital Advisors LLC were 1,220 which equates to market value of $40K and appx 0.00% owners of Ionis Pharmaceuticals
  • On 10/6/2021 shares held by IFP Advisors Inc were 1,720 which equates to market value of $66K and appx 0.00% owners of Ionis Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 220,212 which equates to market value of $8.78M and appx 0.00% owners of Ionis Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 86.71% for Ionis Pharmaceuticals

See More Analyst Rating at: RATING